Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 24, 2022

SELL
$64.88 - $73.64 $269,900 - $306,342
-4,160 Closed
0 $0
Q2 2021

Jul 28, 2021

SELL
$63.47 - $69.35 $5,712 - $6,241
-90 Reduced 2.12%
4,160 $286,000
Q1 2021

Apr 27, 2021

SELL
$60.0 - $68.46 $19,500 - $22,249
-325 Reduced 7.1%
4,250 $275,000
Q4 2020

Jan 22, 2021

SELL
$56.65 - $64.55 $122,477 - $139,557
-2,162 Reduced 32.09%
4,575 $267,000
Q1 2020

Apr 14, 2020

SELL
$62.63 - $80.22 $8,768 - $11,230
-140 Reduced 2.04%
6,737 $504,000
Q4 2019

Jan 09, 2020

SELL
$61.62 - $67.78 $45,290 - $49,818
-735 Reduced 9.66%
6,877 $447,000
Q3 2019

Oct 11, 2019

BUY
$62.51 - $69.0 $4,813 - $5,313
77 Added 1.02%
7,612 $482,000
Q2 2019

Jul 16, 2019

BUY
$61.87 - $69.38 $32,791 - $36,771
530 Added 7.57%
7,535 $509,000
Q4 2018

Jan 14, 2019

BUY
$60.54 - $79.0 $13,197 - $17,222
218 Added 3.21%
7,005 $438,000
Q3 2017

Oct 20, 2017

BUY
$72.11 - $85.47 $489,410 - $580,084
6,787
6,787 $550,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Northside Capital Management, LLC Portfolio

Follow Northside Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northside Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Northside Capital Management, LLC with notifications on news.